On October 21, 2025, Quoin Pharmaceuticals announced that the FDA granted Orphan Drug Designation to its lead product, QRX003, for treating Netherton Syndrome. This designation provides benefits like tax credits for clinical testing and potential market exclusivity, as QRX003 aims to be the first approved treatment for this rare disease.